More news: Research
Agency / Source: Aciont, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Aciont® Awarded Two Qualifying Therapeutic Discovery Project Grants Totaling $489K - Aciont, Inc. was awarded a grant from the federal government under the Qualifying Therapeutic Discovery Project Program
Aciont® Awarded Two Qualifying Therapeutic Discovery Project Grants Totaling $489K

 

PRZOOM - /newswire/ - Salt Lake City, UT, United States, 2010/11/04 - Aciont, Inc. was awarded a grant from the federal government under the Qualifying Therapeutic Discovery Project Program.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Aciont, Inc. announced today that it has been awarded $488,958 to support two projects under the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program. Aciont submitted only the following two applications to the program of which both were funded at the maximum allocation amount:

• “Iontophoretic Treatment for Age-related Macular Degeneration and Diabetic Retinopathy”; and
• “Non-Invasive Treatment for Severe Uveitis and Related Posterior Eye Inflammation Diseases.”

“Aciont Inc. is pleased that the U.S. Federal government further recognizes and supports our important ophthalmology projects that intend to develop non-invasive treatments for sight threatening diseases; we intend to use these funds to help accelerate our commercialization plans,” said John Higuchi, CEO, Aciont.

The QTDP program was established as a result of the Patient Protection and Affordable Care Act of 2010 to provide tax credits or grants to taxpayers with no more than 250 employees in an amount equal to 50% of eligible 2009 and 2010 expenses related to a qualifying therapeutic discovery project. To be eligible for the program, projects must show reasonable potential to do the following: result in new therapies to treat areas of unmet medical need; prevent, detect, or treat chronic or acute disease and conditions; reduce long-term health care costs; or significantly advance the goal of curing cancer within a 30-year period. Projects were selected jointly by the Treasury Department and the Department of Health and Human Services.

Aciont, Inc. (aciont.com) is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Aciont, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Aciont® Awarded Two Qualifying Therapeutic Discovery Project Grants Totaling $489K

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Jillian Conrad - Aciont.com 
801-359-3461 admin[.]aciont.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Aciont, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Aciont, Inc. / Company Profile


Read Research Most Recent Related Press Releases:

Peking University and Thales Sign A Contract to Develop A Very High Peak Power Laser System in China
University of Antwerp and Imec Launch Crowdscan - A New Spin-off to Measure Crowds without Compromising Personal Privacy
BASF Supports Search for Active Ingredients to Combat Coronavirus SARS-CoV-2
Bruker Corporation Announces Successful Installation of World’s First 1.2 GHz NMR System Enables Novel Functional Structural Biology Research
Innovation Platform Nexplore Forms Research Cooperation with TU Darmstadt
Increasing Demand for Real Time Access Boosts the Global Image Recognition Market At 21.00% CAGR According to Inkwood Research
Innovative MYRRHA Research Reactor Starting to Take Shape
BASF and BNP Brinkmann Acting as Project Partners to Support Current DLR Research on the Future of Mobility
BASF and CTIBiotech to Develop First 3D Bioprinted Human Reconstructed Skin Including Immune Macrophages
Bruker Announces Acquisition of Preclinical and Molecular Imaging Research Software Provider PMOD Technologies, LLC

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  JobsWare.com

Visit  VR CORPORATENEXT

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today